Emerging Treatment Modalities in Metastatic Breast Cancer: Highlights from SABCS 2022 and Beyond - Episode 4

The Role of Capivasertib in ER+/HER- mBC

,

Komal Jhaveri, MD, FACP, discusses the role of capivasertib in ER-positive HER2-negative mBC and the design and outcomes of the CAPItello 291 trial.

EP. 1: Overview of ER+/HER2- Metastatic Breast Cancer (mBC)
EP. 2: Standards of Care in the Frontline Treatment of ER+/HER2- mBC
EP. 3: Use of Second-Generation Oral SERDs in ER+/HER2- mBC
Now Viewing
EP. 4: The Role of Capivasertib in ER+/HER- mBC
EP. 5: Standard Practices for the Management of Triple-Negative Breast Cancer (TNBC)
EP. 6: The Role of ADCs in the Treatment of TNBC
EP. 7: Investigational ADCs for Treatment of TNBC
EP. 8: Emerging Concepts in mBC Treatment

Related Content:

Emerging Treatment Modalities in Metastatic Breast Cancer: Highlights from SABCS 2022 and BeyondBreast Cancer
Pelareorep Plus Chemo Improves OS in Endocrine-Refractory HR+/HER2– Advanced Breast Cancer
Elacestrant Plus Abemaciclib Demonstrates Clinical Benefit in Pretreated ER+/HER2– Metastatic Breast Cancer
Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer